Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres
Clin Exp Dermatol
.
2023 Nov 16;48(12):1376-1378.
doi: 10.1093/ced/llad277.
Authors
Stefano Buffon
1
2
,
Silvia Alberti Violetti
1
2
,
Gianluca Avallone
3
,
Luigia Venegoni
2
,
Angelo V Marzano
1
2
,
Luca Mastorino
3
,
Paolo Fava
3
,
Simone Ribero
3
,
Pietro Quaglino
3
,
Michela Ortoncelli
3
,
Silvia M Ferrucci
1
Affiliations
1
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
2
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
3
Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
PMID:
37596961
DOI:
10.1093/ced/llad277
No abstract available
MeSH terms
Humans
Mycosis Fungoides* / drug therapy
Sezary Syndrome* / drug therapy
Skin Neoplasms* / drug therapy
Tertiary Care Centers
Substances
dupilumab